642 related articles for article (PubMed ID: 18824292)
1. HDAC family: What are the cancer relevant targets?
Witt O; Deubzer HE; Milde T; Oehme I
Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
[TBL] [Abstract][Full Text] [Related]
2. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
5. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.
Gregoretti IV; Lee YM; Goodson HV
J Mol Biol; 2004 Apr; 338(1):17-31. PubMed ID: 15050820
[TBL] [Abstract][Full Text] [Related]
6. Targeting of HDAC8 and investigational inhibitors in neuroblastoma.
Oehme I; Deubzer HE; Lodrini M; Milde T; Witt O
Expert Opin Investig Drugs; 2009 Nov; 18(11):1605-17. PubMed ID: 19780707
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific histone deacetylase inhibitors: the next step?
Balasubramanian S; Verner E; Buggy JJ
Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
[TBL] [Abstract][Full Text] [Related]
8. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
10. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
13. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
15. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
16. SIRTUIN 1: regulating the regulator.
Zschoernig B; Mahlknecht U
Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Thomas S; Munster PN
Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: overview and perspectives.
Dokmanovic M; Clarke C; Marks PA
Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
